



International **Bi**opharmaceutical Industry

# **MEDIA INFORMATION 2022**

[www.international-biopharma.com](http://www.international-biopharma.com)

# OUR BRAND

## Supporting the Industry Through Communication

Only through a combination of strong science and deep operational excellence will the biopharma industry be able to fulfill its potential to transform the health expectations of millions of people across the globe, successfully navigating both the promising and challenging elements of the sector.

In order to achieve this objective, it is essential for the executives of this dynamic industry to constantly keep themselves educated in the latest technology, market information, regulatory guidelines to gain a competitive edge.

Peer reviewed by our carefully selected editorial advisory panel, and extensive research network, IBI, provides a proven supportive means of communication to the biopharmaceutical industry, the latest in research and technology innovations, regulatory guidelines, marketing and communication strategies which will enable them to be more efficient, bring products to market faster.




## Our Focus

Our authors – who share their knowledge and offer practical experiences with our readers – are executives, managers, and investigators who are involved in the best practice in outsourcing management for the pharmaceutical and bio-pharmaceutical industries.

## Our Readers

With a global audience of 37,615\* engaged pharmaceutical and bio-pharmaceutical professionals, IBI connects you to the industry executives who are most receptive to your marketing message.





## OUR EXPERTS



**Dr. Jeff  
Sherman**

Dr. Sherman is the Research & Development Advisor to the International Biopharmaceutical Industry Journal. Dr Sherman's serves as Executive VP for Development and Regulatory affairs and Chief Medical Officer in renowned Pharmaceutical & Biopharmaceutical organisations. Dr. Sherman is a member of the Global Genes Medical and Scientific Advisory Board and involved with the National Organization for Rare Disorders (NORD) and the European Organisation for Rare Diseases (EURORDIS). He is also an adjunct assistant professor of medicine at the Northwestern University Feinberg School of Medicine and is a member of a number of professional societies, as well as a diplomat of the National Board of Medical Examiners and the American Board of Internal Medicine.

### IBI Editorial Advisory Board

Our Editorial Advisory Board ensures the credibility and accuracy of our content through their expertise. The Board members come from all walks of the industry – Regulatory agencies, Ministry of Health, Pharmaceutical & Bio-Pharmaceutical Companies, and all other stakeholders. They have experience with Biopharmaceutical Development, Monoclonal Antibodies, Biosimilars / Biobetters, Protein Therapeutics, Vaccines, Cell & Gene Therapies, Antibody Drug Conjugates, Manufacturing, Funding & Investment. These international experts offer their mastery to review manuscripts, suggest topics and advise editors on industry issues. Through their contributions, our readers benefit by receiving credible, practical and relevant articles and commentaries.



**Dr. Charles  
Chiedza Maponga**

Dr Charles Chiedza Maponga, serves on the advisory and review board for the IBI Journal. Dr Maponga is research team member and Pharmacy Consultant for the University of Zimbabwe and University of California at San Francisco's collaborative research program in women's health where he provides advice on Pharmacy related issues. He has extensive training and skills in the implementation of antiretroviral medication. He is co-Principal Investigator in a recently awarded NIH Fogarty International Center's AIDS International Training and Research Program (AITRP) grant to develop HIV Clinical Pharmacology Research Programs in southern Africa.



**Dr. Venki  
Ramakrishnan**

Dr Ramakrishnan, sits on the editorial advisory board of the IBI Journal. Venkatraman "Venki" Ramakrishnan is a British-American structural biologist who is the current President of the Royal Society. In 2009, he shared the Nobel Prize in Chemistry "for studies of the structure and function of the ribosome. He was elected President of the Royal Society for a term of five years starting in 2015. Since 1999, he has worked as a group leader at the Medical Research Council (MRC) Laboratory of Molecular Biology (LMB) on the Cambridge Biomedical Campus.



# CIRCULATION & READERSHIP

## In Print

International Biopharmaceutical Industry (IBI) is a globally distributed publication with a presence across the world. Each quarterly issue has a print copy distribution figure of **24,300** copies, providing strong access to the International Market. IBI is sent directly to key decision makers in the Bio-pharmaceutical Industry, addressing all stakeholders.

### READERSHIP BY JOB FUNCTION

22%	Corporate Management
12%	Heads of Preclinical & Early Phase
10%	Heads of regulatory Affairs
10%	Heads of Scientific Research
8%	Heads of Drug Delivery & Development
7%	Heads of Procurement
6%	Heads of Formulation Development
5%	Medical Directors
5%	Logistics & Supply Chain Managers
5%	Heads of API & Chemical Production
5%	Heads of Bio Processing
5%	Laboratory Management


### CIRCULATION

Print Subscribers	<b>24,300</b>
Digital Subscribers	<b>15,219</b>

### DIRECT MAIL

IBI E-Newsletters	<b>15,219</b>
E-Blast	<b>14,428</b>


## BUSINESS & INDUSTRIES



## In Digital

**IBI E-Newsletter** – provides the latest business news, product news, events, technical papers, and links to company information and services. This gives you the regular and latest update on products and services offered to the global bio-pharmaceutical industry.

**IBI E-Newsletter & IBI E-Blast** is sent to more than **15,219** professionals working for the leading bio-pharmaceutical & pharmaceutical companies, pre-clinical and scientific research organisations, other vendors, service providers, government & non-government agencies.



**AMERICA + CANADA**

**EUROPE + RUSSIA**

**ASIA**

**REST OF THE WORLD**

Print: 8,657

Print: 9,526

Print: 3,166

Print: 2,951

Digital: 5,302

Digital: 5,312

Digital: 2,391

Digital: 2,214

# RATES & DATA

## Print Media

### PRINT ADVERTISEMENT

Double Page	<b>£ 5,250</b>
Full Page	<b>£ 2,850</b>
Half Page (Vertical / Horizontal)	<b>£ 1,650</b>
<b>Prime Positions:</b>	
Inside Front Cover	<b>£ 5,950</b>
Inside Back Cover	<b>£ 4,850</b>
Outside Back Cover	<b>£ 7,250</b>
Page Opposite Contents	<b>£ 3,750</b>
Page Opposite Editor's Letter	<b>£ 3,750</b>
1 Page Corporate Profile	<b>£ 2,000</b>
Front Cover LOGO	<b>£ 1,500</b>

Discounts apply for series bookings.

Inserts, reprints and recruitment advertisers' rates are available on application.

For more information contact: [info@senglobalcoms.com](mailto:info@senglobalcoms.com)

### MECHANICAL SPECIFICATIONS

(In mm, Height x Width, with Type, Trim, Bleed)

	Type	Trim	Bleed
Full Page:	261 x 181	297 x 210	303 x 216
½ Pages (horizontal)	135 x 186	148 x 210	154 x 216
½ Pages (vertical)	273 x 92	297 x 105	303 x 108

Please supply digitally, ideally a press ready PDF.

Alternatively supply as a flat image file (Tiff, Jpeg, EPS, PSD etc) ensuring that all fonts are embedded, images are High-resolution and the file is CMYK.

## Digital Media


### WEBSITE ADVERTISEMENT

Home Page Pop-up 640 x 480 px	<b>£2,500 for 3 mos</b>
Corner Peel (Specs sent upon request)	<b>£1,800 for 3 mos</b>
Leader Board 728 x 90 px	<b>£1,200 for 3 mos</b>
Rectangular (right/left column) 300 x 250 px	<b>£1,000 per 3 mos</b>
Skyscraper (right/left column) 300 x 600 px	<b>£1,000 per 3 mos</b>
Host Videos	<b>£1,000 for 3 mos</b>
Sponsored Articles	<b>£1,000 per 3 mos</b>
Events Listing	<b>£250 for 3 mos</b>
News	<b>£250 for 3 mos</b>

## E-Blast & E-Newsletter Campaign

IBI holds a secured database of over **15,219** professionals working for the leading pharmaceutical, mid-sized bio technology companies, who have given their consent to receive a Weekly Electronic Newsletter and any third party relevant supplier information. IBI provides a direct communication link to these high net worth individuals through its Electronic Campaign Platforms.

<b>E-Newsletter</b>	£250 Per Week (Minimum of 4 weeks booking)
<b>E-Blast: HTML E Blast</b>	£1,298 Per Campaign








# DIGITAL OFFERINGS

## Online Website Advertising

Display your ad in front of decision makers in the field by placing your banner advertisement on [international-biopharma.com](http://international-biopharma.com).

✓ Content Tactic: Branding/Awareness, Web Traffic




The screenshot shows the IBI website homepage. At the top, there's a navigation bar with links like HOME PAGE, CURRENT FEATURES/VOLUME 2 ISSUE 3, EDITORIAL ARCHIVE, ARCHIVED ISSUES, EVENTS, and MORE. Below the navigation bar, there are several featured articles and advertisements. On the left, there's a section for 'CURRENT EDITION - VOLUME 2 ISSUE 3' with a cover image. In the center, there are articles such as 'Data-driven Decision-making and Real-world Evidence: Current and Emerging Trends', 'New Immunotherapies Need New Models to Reflect New Modalities', 'Cognitive Pharmacovigilance: Business Perspective', 'Transmucosal Drug Delivery to the Brain via the Nose', and 'Inhalation Advances'. On the right, there are advertisements for 'SYNBI MARKE', 'BIO-EUROPE', 'BioForward BIRMINGHAM 11 OCTOBER 2019', 'FUJIFILM PYROSTAR', 'Wickham Laboratories', and 'pci CLINICAL SERVICES'. At the bottom, there's a section for 'EXPRESS'ION' and a small section for 'ARE YOU LOOKING FOR EXPERTS IN MICROBIAL PRODUCTION?'.

## Corporate Profile Listing

Exclusive resource section on the International Bio-Pharmaceutical Industry ([international-biopharma.com](http://international-biopharma.com)) website where your company can disseminate collateral, videos, 900 word company descriptions, USP to drive website traffic, generate leads and more. Your content block is not an ad unit and does not go into rotation so it is visible 24/7.

✓ Content Tactic: Branding/Awareness, Web Traffic



The screenshot shows the Richter-Helm corporate profile listing. At the top, there's the company name 'Richter-Helm' and its logo. Below the name, there are social media icons for Facebook, Twitter, Google+, LinkedIn, and Pinterest. To the right, it says 'Views: 290'. Below the social media icons, there's a section titled 'GERMAN RELIABILITY AND THOROUGHNESS'. The main text describes Richter-Helm as a Hamburg, Germany-based contract development and manufacturing company specialized in products derived from bacteria and yeasts, with a proven 30-year track record. It mentions that they provide a comprehensive range of services and customized solutions, and that they have already benefited from their commitment to good manufacturing practice and total transparency. It also mentions that they have a seasoned, 190-strong team that supports clients with process development, supply of products for clinical trials, commercial production, in-house QC testing, and QP release. At the bottom, it mentions that Richter-Helm is the platform of its mother companies Gedeon Richter and Helm AG for worldwide licensing options as well as partnerships for co-development and marketing of microbial derived biopharmaceutical projects.

## Ad Retargeting

Once a visitor leaves [international-biopharma.com](http://international-biopharma.com), your display ad will follow them across the web, driving targeted groups to your website to learn more about your products or services.

✓ Content Tactic: Branding/Awareness, Web Traffic



# DIGITAL OFFERINGS

## BOOST – Custom Targeted Email Campaign

BOOST is a highly targeted, data driven, HTML E-Campaign tool. BOOST contains over 100,000 decision makers from global companies involved in the pharmaceutical and scientific industries served by our leading publications.


✓ Content Tactic: Web Traffic, Lead Generation

### SONOTEC



**Challenged by the need for highly accurate non-invasive flow measurement in your upstream and downstream processes?**

SONOFLOW CO.55 sensors has been successfully placed at critical points in upstream and downstream processes to fulfil regulatory goals of the Process Analytical Technology (PAT) framework in continuous processing.



[View More](#)




The ultrasonic flow sensor SONOFLOW CO.55 detects the flow rate of liquids in plastic tubes quickly and reliably. The non-invasive sensor has no contact to the medium and is particularly suited for applications with strict hygienic standards. The clamp-on mounting concept eliminates any risk of contamination or leaking.

## IBI – E-Newsletter


IBI – E-Newsletter is published weekly to over **15,219** highly engaged bio-pharmaceutical professionals. Each edition features a premium collection of news, blogs, advertising banners, events, webcasts and more.

IBI Newsletter also contains highlighted articles from the most current edition of the journal.

✓ Content Tactic: Branding/Awareness, Web Traffic




**IBI WEEKLY**  
LATEST NEWS FROM THE WORLD OF THE BIOPHARMACEUTICAL INDUSTRY



**HIGHLIGHTED ARTICLES**

- \*Exploiting Epigenetics To Systematically Optimise Culture Conditions For Cellular Therapies
- \*Developments In Non-Invasive Preclinical Lung Imaging To Support Drug Discovery
- \*Why Patient Diversity In Research Must Become The Norm



**BRING NEW THERAPIES TO LIGHT**  
CERBA RESEARCH BIOMARKER DEVELOPMENT

Start With Cerba Research

**Vertex, looking to broaden its gene editing abilities, asks a young biotech for help**

A freshly inked agreement gives Vertex the right to use tools from Arbor Biotechnology to develop "ex vivo" cell therapies for diseases like Type 1 diabetes and sickle cell, among others.

**AstraZeneca reports study success for rare disease drug acquired in Alexion deal**

With positive results from a Phase 3 trial in hand, the British pharma intends to soon seek regulatory approval for the Wilson disease treatment.

**CUSTOMIZED PROCESS DEVELOPMENT**


**FLEXIBLE CGMP PRODUCTION**

**RELIABLE ANALYTICAL SERVICES**

**APPROVED QUALITY**

**CONTRACT DEVELOPMENT AND MANUFACTURING OF BIOPHARMACEUTICALS**

[LEARN MORE](#)



**FDA grants full approval to Pfizer, BioNTech's coronavirus vaccine**



# DIGITAL MEDIA INFORMATION

## international-biopharma.com

**Average E-Blast CTR: 2.3**

**Average E-Newsletter CTR: 3.1**

**international-biopharma.com** is an online portal providing readers with peer reviewed articles from industry experts, news bulletins, company directory and technical white papers. Website visitors are also able to access the entire archive of IBI articles.

The location report from Google analytics (2020/2021) reveals that over 88% of visits came from Europe, America, Asia and Middle East. The leading countries are United States, United Kingdom, Germany, France, Norway, Switzerland, Italy, China, India, UAE, Saudi Arabia and Australia.

Total amount of Impressions in 2021:

**17,130,224**

Total amount of clicks in 2021:

**66,347**

Total amount of unique Impressions in 2021:

**14,645,432**

Total amount of unique clicks in 2021:

**47,452**

## Social Media



[www.twitter.com/IbiJournal](https://www.twitter.com/IbiJournal)



[www.facebook.com/international-biopharma](https://www.facebook.com/international-biopharma)



## White Papers

**international-biopharma.com** presents technical white papers, highlighting each contributing organisation's expertise and knowledge within its fields. White papers appear on the site in an accessible, searchable archive, which can be easily viewed and downloaded by readers.

## Digital Journal and eNewsletter

The digital magazine edition of IBI is a fully interactive, page turning version of the print magazine. The e-Journal is emailed to a growing list of digital subscribers in a regular newsletter, expanding IBI's print circulation to a broad international readership.

## Company Capabilities

**international-biopharma.com's** online company profile listings provides a guide for readers wishing to find out more about service providers. The company listings features company contact information, along with 800 word description, company logo and website links.

# EDITORIAL CALENDAR 2022

IBI provides the biopharmaceutical industry with comprehensive coverage of key scientific, technology, regulatory and business topics. The editorial mix of peer-reviewed papers, practical advice on managing bioprocessing and technology, regulatory and business columns, and expert commentary provides comprehensive coverage of upstream and downstream processing, manufacturing operations, regulations, formulation, scale-up/technology transfer, drug delivery, analytical testing and more.

The insight and analysis covers biologic – based therapies including We will report on emerging trends, strategies and best practices in the key areas.

IBI Publishes, Peer Reviewed papers in the form of technical case studies, application notes; topical literature or patent reviews; novel research; or science based opinion papers. All papers undergo a peer review process by IBI's Editorial Advisory Board of scientists, managers, directors and consultants.

## Peer Review Protocol

### Criteria for Publication

Provides strong evidence for its conclusions.  
• Novel • Unbiased • Non Promotional. Of extreme importance to stakeholders in the Pharmaceutical and Biopharmaceutical Industry. In general, to be acceptable, a paper should represent an advance in understanding likely to influence thinking in the field. There should be a good and clear reason why the work deserves the visibility of publication in a Pharma Publications journal rather than in a different journal.

## Author Guidelines

A typical article will be about 2000–2500 words. You can include from 4–5 images, graphs or graphics with the article.

The article must be sent to us in a Word Document format, and all associate images should be supplied separately in a High Resolution (PDF, Jpeg, PNG) file, 300 dpi min.

## Editorial Sections

include but are not limited to:

Monoclonal Antibodies

Biosimilars/Biobetters

Protein Therapeutics

Vaccines

Cell & Gene Therapies

Antibody Drug Conjugates

Biopharmaceutical Development

Manufacturing: Upstream processing

Manufacturing: Downstream processing

Manufacturing: Quality and regulations

Analytics

Facilities and equipment

Laboratory Operations

Packaging Logistics & Supply chain

Intellectual Property

Funding & Investment

**Article Title:** Should not be more than 10 words in length.

**Author Bios:** Author Bios should not be more than 60 words in length. Please also supply us with Author Email.

**Author Picture(s):** Please send Author(s) Headshots in High Resolution (300dpi min), (Jpeg, PDF format)

Please visit our website [international-biopharma.com](http://international-biopharma.com), or request from our editorial team the entire Peer Review Protocol, and the Author Guidelines.

# EDITORIAL CALENDAR 2022

## February

Volume 5 Issue 1

Issue Date: 25<sup>th</sup> February 2022

Editorial Submission Deadline: 10<sup>th</sup> January 2022

### Regulatory & Compliance

- Recent developments in cellular immunotherapy: IP and patents
- The business case for the identification of medicinal products (IDMP) implementation
- Regulation of biotech products in the global pharma market
- API Development and Approval Trends
- Bio Business: Economic Development

### Research / Innovation / Development

- Challenges in the development of small-molecule drugs
- Automation of biological assays
- Challenges for formulation and delivery of nanotech drugs
- Solutions for optimised delivery
- The healthcare digitisation trends
- Biomarker identification for targeted therapies
- Biologics
- The penetration of biologic drugs: monoclonal antibodies, recombinant proteins, peptides, cell and gene therapy products

### Preclinical & Clinical Research

- Animal models: Developing standardised animal models to help establish accurate results in preclinical development
- Optimal trial design strategies for phase I and proof of principle/concept.
- Early stage trials / Viral vectors
- Vaccines

### Manufacturing / Technology Platforms

- **Early Development Pipeline:** Monoclonal Antibodies
- **Upstream Processing:** Cell Culture
- **Downstream Processing:** Separation & Purification
- **Manufacturing:** Fluid Handling Systems
- **Bioprocessing:** Protein biopharmaceuticals
- **Technology:** New methods for rapid acquisition of data sets in cloud-based storage

### Operations


- Process Monitoring/Controls
- The cGMP standards for clinical research – how to meet the requirements for identity, strength, quality and purity in API manufacturing

### Analytics

- Extractables & Leachables Testing

### Supply Chain Management

- Achieving supply chain flexibility: 3PL partnerships
- IoT solutions
- Supply chain innovations
- The sustainability issue: Leaner and Greener
- The impact of digitalisation





# EDITORIAL CALENDAR 2022

**May**

**Volume 5 Issue 2**

Issue Date:

25<sup>th</sup> May 2022

Editorial Submission Deadline:

20<sup>th</sup> March 2022

## Regulatory & Compliance

- Navigating the shifting global and national regulatory landscape
- Fighting counterfeiting/ serialisation
- Process Validation
- Managing data in the New Health Economy
- **Bio Business:** Partnering

## Research / Innovation / Development

- Biologics
- Recombinant therapeutics
- Immunotherapy
- Antibody drug conjugates
- Gene and cell therapies
- Biotech ways of improving the productivity of drug development:
- Rational drug design, combinatorial chemistry, in silico experimentation
- The rising tide of functional data from study of the human and other genomes
- High throughput proteomics

## Preclinical & Clinical Research

- Preclinical Infectious Disease Research
- Optimizing the design of clinical trials
- Toxicology studies, molecular biomarkers, imaging and companion diagnostics
- Oncolytic Viruses

## Manufacturing / Technology Platforms

- **Early Development Pipeline:** Biologic-Drug Formulation
- **Upstream Processing:** Cell Culture
- **Downstream Processing:** Cell Harvesting
- **Manufacturing:** Protein Therapeutics Development
- **Bioprocessing:** Bioprocessing of New Medicines
- **Technology:** Therapeutic proteins, polysaccharides, vaccines, and diagnostics

## Operations


- Facilities
- Advancements in drug discovery technologies: such as iPS cells, automated high content screening, patch clamp, gene editing and DNA encoded libraries

## Analytics

- Analytical technology for biopharmaceuticals

## Supply Chain Management

- Managing global supply chains
- Predicting security and supply risks
- Building flexible supply chains
- Supply chain visibility Optimisation and cost management



# EDITORIAL CALENDAR 2022

## August

Volume 5 Issue 3

Issue Date: 25<sup>th</sup> August 2022

Editorial Submission Deadline: 20<sup>th</sup> June 2022

### Regulatory & Compliance

- Pricing and reimbursement
- Boosting the drug pipelines through acquisitions, licensing deals and research collaborations
- The harmonisation of regulations & policies [keeping up with the rising demands of regulators (FDA)]
- Bio Business: Intellectual Property

### Research / Innovation / Development

- High-throughput screening (HTS) solutions
- The increasing use of protein arrays and DNA microarrays
- The rising number of potential drug targets for screening
- Chemical synthesis and biological testing
- The potential of biosimilars
- Current methods of rational drug design
- Products for virtual screening and database building
- Optimising bioavailability using particle engineering, improving drug safety and ADME, and genomics

### Preclinical & Clinical Research

- Preclinical Decision Making – Predict & Minimise Risk
- Providing better safety profiles of trial compounds
- Cell / Gene / Stemcell Therapy
- Clinical Monitoring

### Manufacturing / Technology Platforms

- **Early Development Pipeline:** Protein Therapeutics
- **Upstream Processing:** Bioreactors
- **Downstream Processing:** Cell Harvesting
- **Manufacturing:** New manufacturing technology platforms for Biosimilars
- **Bioprocessing:** Single-use systems and disposable devices
- **Technology:** High resolution medical imaging

### Operations


- Equipments
- Lab Operations
- Work stations, automating assays, and sample preparation

### Analytics

- Microbial Contamination

### Supply Chain Management

- Achieving supply chain flexibility: 3PL partnerships
- IoT solutions
- Supply chain innovations
- The sustainability issue: Leaner and Greener
- The impact of digitalisation



# EDITORIAL CALENDAR 2022

## December

Volume 5 Issue 4

Issue Date: 15<sup>th</sup> December 2022

Editorial Submission Deadline: 20<sup>th</sup> October 2022

### Regulatory & Compliance

- Safety and regulatory solutions for biopharmaceutical companies
- Considerations for Outsourcing the clinical, safety and regulatory activities
- The politics of global regulation
- Outsourcing Development
- **Bio Business:** Partnering

### Research / Innovation / Development

- Biomarkers, molecular imaging, companion diagnostics
- Innovative solutions for immuno-oncology drug discovery
- Target Identification/Target Validation
- Novel therapeutics addressing the unmet needs
- New technologies for reducing the cost and lead time of drug development
- Building capabilities to differentiate in the area of Target Identification/Target Validation
- Use of next-generation sequencing in-vitro diagnostics Opportunities for biologics deliv

### Preclinical & Clinical Research

- The development of cell lines
- Contract manufacturing of developmental biologic drugs to support clinical development at various stages, and bio-analysis and product characterization
- Oncology
- Immunology

### Manufacturing / Technology Platforms

- **Early Development Pipeline:** Biosimilars/Biobetters
- **Upstream Processing:** Expression Systems
- **Downstream Processing:** Residual Impurities
- **Manufacturing:** Fill Finish
- **Bioprocessing:** Process validation
- **Technology:** Lot Release Testing

### Operations


- Lab Operations
- Advancements in drug discovery technologies: such as iPS cells, automated high content screening, patch clamp, gene editing and DNAencoded libraries

### Analytics


- Endotoxin Testing

### Supply Chain Management

- The Big Data Revolution
- Integration of medical apps
- Integrating Serialization and Track and Trace Systems into the Supply Chain
- Data delivery: how to collect, analyze and package data for success





**Contact:**

International Biopharmaceutical Industry  
Unit 5.02, E1 Studios, 7 Whitechapel Road,  
E1 1DU, United Kingdom

**T:** +44 (0) 204 5417569  
**E:** [info@senglobalcoms.com](mailto:info@senglobalcoms.com)  
**W:** [international-biopharma.com](http://international-biopharma.com)

**Advertising Contact:**

Ty Eastman, [ty@senglobalcoms.com](mailto:ty@senglobalcoms.com)

**Editorial:**

Beatriz Romao, [beatriz@senglobalcoms.com](mailto:beatriz@senglobalcoms.com)

**Subscriptions:**

Jessica Dean-Hill, [jessica@senglobalcoms.com](mailto:jessica@senglobalcoms.com)